Silfvast-Kaiser A, Lloyd AA, Menter A (2018) Cutaneous Angiosarcoma in a Psoriasis Patient on Infliximab and Methotrexate Therapy. Int Arch Intern Med 2:006.


© 2018 Silfvast-Kaiser A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE REPORT | OPEN ACCESSDOI: 10.23937/iaim-2017/1710006

Cutaneous Angiosarcoma in a Psoriasis Patient on Infliximab and Methotrexate Therapy

Annika Silfvast-Kaiser1, Amanda Abramson Lloyd2 and Alan Menter1*

1Division of Dermatology, Baylor University Medical Center, Dallas, TX, USA

2Skin and Vein Institute, Encinitas, CA, USA


Angiosarcoma is a soft tissue sarcoma of endothelial origin that can arise in any organ, with an incidence of up to 5% of all malignant cutaneous tumors. It is the 4th most common sarcoma of the skin and typically occurs on the scalp of white men over 60 years of age. Its prognosis is traditionally very poor, with 5-year survival rates reported as low as 11%. Risk factors for cutaneous angiosarcoma have not been clearly established. Herein, we describe a 64-year-old male with a chronic history of psoriasis maintained on methotrexate and infliximab for over 10 years, who presented with a 7-week history of a cluster of reddish-blue, violaceous nodules on his occipital scalp. Biopsy showed classic features of angiosarcoma. He was treated with multimodal therapy. Six years subsequent to his initial diagnosis he continues in remission, with no evident signs of recurrence or further metastases.